APi GroupNYSE: APG

Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing and potential applications in asthma, COPD, and psoriasis. APGE's investigational pipeline includes APG808 and APG990, targeting different inflammatory pathways, enhancing its potential in the I&I market. APGE's strong cash runway and multiple upcoming catalysts, including Phase 2 results for APG777, justify its current valuation premium.

APi Group Corporation (NYSE:APG ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Adam Fee - VP, IR Russell Becker - President and CEO Kevin Krumm - EVP and CFO Conference Call Participants Kenyon Pelletier - Barclays Stephanie Moore - Jefferies Andy Wittmann - Baird Kathryn Thompson - Thompson Research Group Andy Kaplowitz - Citigroup Josh Chan - UBS Jon Tanwanteng - CJS Securities Operator Good morning, ladies and gentlemen and welcome to APi Group's Third Quarter 2024 Financial Results Conference Call. All participants are now in a listen-only mode until the question-and-answer session.

APi (APG) came out with quarterly earnings of $0.51 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.48 per share a year ago.

I downgrade Genuine Parts Company stock from buy to hold due to poor 3Q24 performance and a weak macroeconomic outlook impacting both APG and IPG segments. 3Q24 results showed disappointing comparable sales growth, with APG and IPG segments underperforming, leading to a significant miss on EPS estimates. The outlook remains bleak, with no signs of improvement in consumer spending and industrial production.

APi (APG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Investors need to pay close attention to APi Group (APG) stock based on the movements in the options market lately.

NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) (“APi”) announced today that it intends to release its financial results for the three and nine months ended September 30, 2024, before the market opens on Thursday, October 31, 2024. Third Quarter Earnings Conference Call APi will hold a webcast/dial-in conference call to discuss its financial results at 8:30 a.m. (Eastern Time) on Thursday, October 31, 2024. Participants on the call will include Russell A. Becker, Preside.

APi Group Corporation's earnings are set to grow in Q3 and Q4 2024, despite a recent decline in share price, presenting a Strong Buy opportunity. The company's 13/60/80 framework aims to boost adjusted EBITDA margins, recurring revenue, and free cash flow conversion. APi's aggressive acquisition strategy, including the recent purchase of Elevated Facility Services Group, supports its growth and expansion goals.

Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2025 Initiation of the first clinical trial of APG777 and APG990 combination expected to commence in 2025 with the potential for greater efficacy in atopic dermatitis and across I&I diseases SAN FRANCISCO and WALTHAM, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that it has initiated dosing of healthy volunteers in its first clinical trial for APG990, a novel, subcutaneous (SQ) half-life extended monoclonal antibody targeting OX40L, which is being developed initially as a treatment for people living with AD.